<p>特朗普考虑签署行政命令重新分类大麻</p>
<p>大麻股票因潜在政策变化而上涨</p>
<p>行业对联邦大麻重新分类持乐观态度</p>
<p>作者：特雷弗·哈尼卡特</p>
<p>华盛顿，12 月 17 日（路透社）——据白宫官员透露，特朗普总统预计将在周四谈及放宽联邦对大麻的监管，这一决定可能会大幅逆转数十年来的美国毒品政策。特朗普周一表示，他正在考虑签署行政命令，将大麻重新分类为一种危险性较低的药物——这一决定可能会重塑大麻行业，减轻刑事处罚，并解锁数十亿美元的研究资金。这一转变将代表数十年来联邦大麻政策中最重要的变化之一，将监管降低到普通处方药的水平，并可能为银行和投资者打开长期关闭的大门。特朗普的政策细节尚不明确，但行业持乐观态度。特朗普潜在命令的具体内容尚不清楚。特朗普 “预计将在明天谈及大麻重新分类，但在白宫正式宣布之前，任何关于这一潜在行动的细节都只是猜测，” 一位不愿透露姓名的特朗普政府官员表示。根据美国《受控物质法》，大麻被列为与海洛因、摇头丸和佩约特相同的第一类物质。这一分类表明它具有高度的滥用潜力且目前没有被接受的医疗用途。地方当局通常对大麻实施更宽松的监管，允许医疗或娱乐用途。特朗普周一在椭圆形办公室告诉记者，他正在推动将大麻重新分类为第三类物质，与混合可待因的泰诺、氯胺酮和睾酮并列。“我们对此非常重视，” 他当时表示。潜在政策变化正在推动股价上涨。特朗普可能放宽对这种精神活性药物的限制的初步报道使与大麻相关公司的股票上涨。它们将受益于生产更多的大麻产品。“重新分类将真正打开更多关于如何适当监管和征税大麻的讨论，这将表明联邦政府在寻找解决方案方面是认真的，以便这些企业能够像其他企业一样运营，” 法律事务所 Husch Blackwell 国家大麻业务的合伙人兼共同负责人史蒂夫·莱文表示。资金仍然是大麻生产者面临的最大挑战之一，因为联邦限制使大多数银行和机构投资者无法进入该领域，迫使大麻生产者转向高成本贷款或替代贷方。拜登政府此前已要求卫生与公共服务部审查大麻的分类，该机构建议将其移至第三类分类。毒品执法局必须审查这一建议，并将决定重新分类。“美国潜在的重新分类将是朝着正常化大麻政策、改善研究、支持患者护理以及扩大消费者和患者获得受监管和安全渠道的重要一步，” 加拿大大麻公司 Canopy Growth（WEED.TO）的发言人表示。</p>

<p>特朗普总统预计将就联邦大麻法规的潜在放宽发表讲话，考虑签署行政命令将大麻重新分类为一种危险性较低的药物。这可能会重塑大麻行业，减轻刑事处罚，并解锁研究资金。大麻股票因这一消息而上涨，行业前景乐观。政策的具体细节尚不明确，但重新分类可能会使大麻政策正常化，并改善研究和患者护理</p>

<p>Trump considers executive order to reclassify marijuana</p>
<div class="lb-trans"><p>特朗普考虑签署行政命令重新分类大麻</p>
</div><p>Cannabis stocks rise on potential policy change</p>
<div class="lb-trans"><p>大麻股票因潜在政策变化而上涨</p>
</div><p>Industry optimistic about federal marijuana rescheduling</p>
<div class="lb-trans"><p>行业对联邦大麻重新分类持乐观态度</p>
</div><p>By Trevor Hunnicutt</p>
<div class="lb-trans"><p>作者：特雷弗·哈尼卡特</p>
</div><p>WASHINGTON, Dec 17 (Reuters) - President Donald Trump is expected to address the potential loosening of federal regulations on marijuana on Thursday, according to a White House official, setting up a decision that could sharply reverse decades of U.S. drug policy. Trump said on Monday that he was considering an executive order to reclassify marijuana as a less dangerous drug - a decision that could reshape the cannabis industry, ease criminal penalties and unlock billions in research funding. Such a shift would represent one of the most significant federal changes to marijuana policy in decades, reducing oversight to the level of common prescription drugs and potentially opening doors long closed to banks and investors. DETAILS OF TRUMP’S POLICY ARE UNCLEAR, BUT INDUSTRY IS OPTIMISTIC The precise contents of Trump’s potential order were not immediately clear. While Trump “is currently expected to address marijuana rescheduling tomorrow, any details of this potential action until officially announced by the White House are speculation,” said the Trump administration official, who declined to be named. Under the U.S. Controlled Substances Act, marijuana is listed as a Schedule I substance like heroin, ecstasy and peyote. That classification indicates it has a high potential for abuse and no currently accepted medical use. Local authorities often impose more lax regulations over weed, allowing medical or recreational use. Trump told reporters in the Oval Office on Monday that he was looking at pushing for weed to be reclassified under Schedule III, alongside Tylenol mixed with codeine, ketamine and testosterone. “We are looking at that very strongly,” he said at the time. POTENTIAL POLICY CHANGE IS MOVING STOCK PRICES Initial reports that Trump might loosen restrictions on the psychoactive drug sent stocks of cannabis-related companies higher. They stand to benefit by making more cannabis products. “Rescheduling it would really open the floodgates to more and more smart conversation about the proper way to regulate and tax cannabis, would show that the federal government is real about getting to coming up with a solution so that these businesses can operate like every other business,” said Steve Levine, partner and co-leader of the law firm Husch Blackwell’s national cannabis practice. Funding remains one of the biggest challenges for cannabis producers, as federal restrictions keep most banks and institutional investors out of the sector, forcing pot producers to turn to costly loans or alternative lenders. The Biden administration previously asked the Department of Health and Human Services to review marijuana’s classification, and the agency recommended moving it to Schedule III classification. The Drug Enforcement Administration has to review the recommendation and will decide on the reclassification. “A potential reclassification in the U.S. would be an important step toward normalizing cannabis policy, improving research, supporting patient care, and expanding access to regulated and safe channels for both consumers and patients,” said a spokesperson for Canopy Growth (WEED.TO) , a Canada-based cannabis firm.</p>
<div class="lb-trans"><p>华盛顿，12 月 17 日（路透社）——据白宫官员透露，特朗普总统预计将在周四谈及放宽联邦对大麻的监管，这一决定可能会大幅逆转数十年来的美国毒品政策。特朗普周一表示，他正在考虑签署行政命令，将大麻重新分类为一种危险性较低的药物——这一决定可能会重塑大麻行业，减轻刑事处罚，并解锁数十亿美元的研究资金。这一转变将代表数十年来联邦大麻政策中最重要的变化之一，将监管降低到普通处方药的水平，并可能为银行和投资者打开长期关闭的大门。特朗普的政策细节尚不明确，但行业持乐观态度。特朗普潜在命令的具体内容尚不清楚。特朗普 “预计将在明天谈及大麻重新分类，但在白宫正式宣布之前，任何关于这一潜在行动的细节都只是猜测，” 一位不愿透露姓名的特朗普政府官员表示。根据美国《受控物质法》，大麻被列为与海洛因、摇头丸和佩约特相同的第一类物质。这一分类表明它具有高度的滥用潜力且目前没有被接受的医疗用途。地方当局通常对大麻实施更宽松的监管，允许医疗或娱乐用途。特朗普周一在椭圆形办公室告诉记者，他正在推动将大麻重新分类为第三类物质，与混合可待因的泰诺、氯胺酮和睾酮并列。“我们对此非常重视，” 他当时表示。潜在政策变化正在推动股价上涨。特朗普可能放宽对这种精神活性药物的限制的初步报道使与大麻相关公司的股票上涨。它们将受益于生产更多的大麻产品。“重新分类将真正打开更多关于如何适当监管和征税大麻的讨论，这将表明联邦政府在寻找解决方案方面是认真的，以便这些企业能够像其他企业一样运营，” 法律事务所 Husch Blackwell 国家大麻业务的合伙人兼共同负责人史蒂夫·莱文表示。资金仍然是大麻生产者面临的最大挑战之一，因为联邦限制使大多数银行和机构投资者无法进入该领域，迫使大麻生产者转向高成本贷款或替代贷方。拜登政府此前已要求卫生与公共服务部审查大麻的分类，该机构建议将其移至第三类分类。毒品执法局必须审查这一建议，并将决定重新分类。“美国潜在的重新分类将是朝着正常化大麻政策、改善研究、支持患者护理以及扩大消费者和患者获得受监管和安全渠道的重要一步，” 加拿大大麻公司 Canopy Growth（WEED.TO）的发言人表示。</p>
</div>

Trump expected to address potential easing of marijuana regulations on Thursday

- 特朗普考虑签署行政命令重新分类大麻，可能放松联邦监管。  
- 行业对政策变化持乐观态度，预计将推动大麻股上涨。  
- 此举可能促进研究资金，改善患者护理和访问渠道。

特朗普预计将在周四就可能放宽大麻法规发表讲话